Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), 10x Genomics (TXG) and Kura Oncology (KURA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on scPharmaceuticals (SCPH – Research Report), 10x Genomics (TXG – Research Report) and Kura Oncology (KURA – Research Report).
Confident Investing Starts Here:
scPharmaceuticals (SCPH)
Leerink Partners analyst Roanna Ruiz maintained a Buy rating on scPharmaceuticals on May 14 and set a price target of $11.00. The company's shares closed last Friday at $3.22.
According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.1% and a 28.3% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Lexicon Pharmaceuticals, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for scPharmaceuticals with a $15.60 average price target, implying a 432.4% upside from current levels. In a report issued on May 12, Craig-Hallum also maintained a Buy rating on the stock.
10x Genomics (TXG)
In a report issued on May 14, Puneet Souda from Leerink Partners maintained a Hold rating on 10x Genomics. The company's shares closed last Friday at $9.39, close to its 52-week low of $8.92.
According to TipRanks.com, Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.4% and a 29.8% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.
Currently, the analyst consensus on 10x Genomics is a Moderate Buy with an average price target of $12.56, a 36.2% upside from current levels. In a report issued on May 9, TD Cowen also maintained a Hold rating on the stock with a $11.00 price target.
Kura Oncology (KURA)
In a report issued on May 14, Jonathan Chang from Leerink Partners reiterated a Buy rating on Kura Oncology, with a price target of $23.00. The company's shares closed last Friday at $6.02.
According to TipRanks.com, Chang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.0% and a 28.1% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Bicycle Therapeutics.
Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $22.60, a 279.2% upside from current levels. In a report issued on May 1, TD Cowen also maintained a Buy rating on the stock.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Italgas S.p.A. (I10) Gets a Hold from Barclays
In a report released today, Jose Ruiz from Barclays maintained a Hold rating on Italgas S.p.A. (I10 – Research Report), with a price target of €7.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Ruiz covers the Utilities sector, focusing on stocks such as Endesa SA, Italgas S.p.A., and Enel S.p.A.. According to TipRanks, Ruiz has an average return of 4.0% and a 60.95% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Italgas S.p.A. with a €7.03 average price target. The company has a one-year high of €7.30 and a one-year low of €4.57. Currently, Italgas S.p.A. has an average volume of 1,820. Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of I10 in relation to earlier this year.
San Francisco Chronicle
4 hours ago
- San Francisco Chronicle
Here are 17 activities State Farm considers too risky to insure under one California policy
What do corn mazes, mushroom farms and professional athletes have in common? They all have the dubious honor of being considered too risky to insure under a State Farm policy that offers extra liability coverage, per a filing earlier this year. The underwriting guidelines apply to the embattled insurer's California Personal Liability Umbrella Program, a product for policyholders who want protection beyond what's included in a basic personal liability policy. It provides a minimum of $1 million for covered claims, which could include liabilities like steep attorney's fees, damages from a lawsuit, or medical bills for someone the policyholder injured. State Farm requested a 39% rate hike for the product earlier this year, citing the need to offset rising claim costs stemming from 'more accidents, escalating medical bills and larger legal settlements,' a company spokesperson said at the time. State regulators have yet to decide whether to approve the hike. That request is separate from State Farm's home insurance rate increases; the company received approval from state regulators in May to temporarily increase rates by an average of 17% and is still pursuing a permanent 30% rate hike, which would add an additional 11%. State Farm stopped accepting new applications for the umbrella policy in California two years ago, according to the filing. But for customers considering renewing their coverage, State Farm's underwriting guidelines include a laundry list of disqualifying activities or characteristics. Some might not raise any eyebrows — applicants with prior fraud convictions are barred, for example — but other restrictions are more esoteric, like farms that offer Pick-Your-Own produce. Here's a selection of the sometimes eclectic list of traits and activities State Farm considers 'unacceptable': Highly specific underwriting guidelines for personal liability umbrella policies is not a new phenomenon, though insurers sometimes add new ineligibilities if they deem activities to have become riskier over time, said Janet Ruiz, a spokesperson for the Insurance Information Institute. She declined to comment specifically on State Farm's guidelines. Premiums for umbrella policies have increased in recent years in part due to rising medical costs, more lawsuits and occasional 'astronomical verdicts' in some legal cases, Ruiz said. She still recommends umbrella policies, especially for people with significant assets, but she is also hoping for tort reform to reign in rising legal payouts. 'It's an important balance,' Ruiz said. 'People should get paid for the damages, but when they get excessive amounts, we all pay for it, in the cost but also some of the exclusions.'
Business Insider
5 hours ago
- Business Insider
Analysts Offer Insights on Technology Companies: PagerDuty (PD) and AvePoint (AVPT)
Companies in the Technology sector have received a lot of coverage today as analysts weigh in on PagerDuty (PD – Research Report) and AvePoint (AVPT – Research Report). Confident Investing Starts Here: PagerDuty (PD) Monness analyst Brian White maintained a Hold rating on PagerDuty on May 30. The company's shares closed last Friday at $14.26. According to White is a top 100 analyst with an average return of 17.7% and a 67.1% success rate. White covers the Technology sector, focusing on stocks such as Salesforce, Snowflake, and MongoDB. Currently, the analyst consensus on PagerDuty is a Hold with an average price target of $18.70, implying a 24.8% upside from current levels. In a report issued on May 21, TD Cowen also maintained a Hold rating on the stock with a $18.00 price target. AvePoint (AVPT) The company's shares closed last Friday at $18.65, close to its 52-week high of $19.90. According to Wood is a 5-star analyst with an average return of 15.0% and a 62.4% success rate. Wood covers the Technology sector, focusing on stocks such as Onestream, Inc. Class A, Klaviyo, Inc. Class A, and Rimini Street. Currently, the analyst consensus on AvePoint is a Strong Buy with an average price target of $21.00.
